Payment overview · 2025
General Payments
$2,786.38
69 reported records · 16 companies
Healthcare provider profile · identity verified
Kiumarce Kashi, MD.
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1629081500
Verified facts
What the public records show
CMS Open Payments records show Kiumarce Kashi, MD. received $2,786.38 in general payments during 2025 across 69 reported records.
Inspire Medical Systems, Inc. accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $1,412.82 | 50.7% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $236.05 | 8.5% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $153.81 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.32 | 5.4% | 8 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $150.00 | 5.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.22 | 4.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.20 | 3.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.82 | 2.4% | 3 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $65.40 | 2.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.25 | 2.3% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.20 | 2.2% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $53.24 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.06 | 1.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.90 | 1.6% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $38.06 | 1.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.03 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,940.94 | 62 |
| Travel and Lodging | $695.44 | 6 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $1,412.82 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $200.30 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $200.30 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $153.81 | 2 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $124.22 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $118.53 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.85 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.02 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.82 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.82 | 3 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $65.40 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.25 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $62.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.10 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $53.24 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.90 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 219 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 70 |
| Lisinopril | Lisinopril | 134 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 51 |
| Losartan Potassium | Losartan Potassium | 113 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 37 |
| Furosemide | Furosemide | 79 | 36 |
| Famotidine | Famotidine | 78 | 33 |
| Gabapentin | Gabapentin | 77 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 22 |
| Montelukast Sodium | Montelukast Sodium | 59 | 26 |
| Ozempic | Semaglutide | 59 | 19 |
| Metformin Hcl | Metformin Hcl | 55 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 20 |
| Sertraline Hcl | Sertraline Hcl | 51 | 20 |
| Trazodone Hcl | Trazodone Hcl | 50 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 39 |
| Jardiance | Empagliflozin | 45 | 25 |
| Omeprazole | Omeprazole | 42 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 16 |
| Simvastatin | Simvastatin | 39 | 13 |
| Allopurinol | Allopurinol | 38 | 13 |
| Carvedilol | Carvedilol | 36 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 14 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Eliquis | Apixaban | 33 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 16 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | 15 |
| Glipizide | Glipizide | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Atenolol | Atenolol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | 14 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Alprazolam | Alprazolam | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Micardis | Telmisartan | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,786.38 · 69 records | Inspire Medical Systems, Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, LUMRYZ, MOUNJARO, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Rybelsus, Sunosi, UBRELVY, WAKIX, XYREM, XYWAV, ZEPBOUND, remede System | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error